Key Details
Price
$1.38Annual ROE
-357.84%Beta
-0.23Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 28, 2025Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vincerx Pharma, Inc. (NASDAQ: VINC) and Oqory, Inc. is fair to Vincerx shareholders. Upon completion of the proposed transaction, Vincerx equity holders will hold about 5% of the combined company. Halper Sadeh encourages Vincerx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, Oqory merge with Vincerx and Oqory equity holders will own approximately 95% of the combined en.
Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
While initial findings for Vincerx's (VINC) new drug did indicate some effectiveness against tumors, the stock price fell after analysts expressed disappointment with the results.
Shares of Vincerx Pharma (NASDAQ: VINC) are dropping significantly on Tuesday following the release of initial data from a Phase 1 clinical trial. The early study results showed promise for Vincerx Pharma's cancer therapies.
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC) Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC)
FAQ
- What is the ticker symbol for Vincerx Pharma?
- Does Vincerx Pharma pay dividends?
- What sector is Vincerx Pharma in?
- What industry is Vincerx Pharma in?
- What country is Vincerx Pharma based in?
- When did Vincerx Pharma go public?
- Is Vincerx Pharma in the S&P 500?
- Is Vincerx Pharma in the NASDAQ 100?
- Is Vincerx Pharma in the Dow Jones?
- When was Vincerx Pharma's last earnings report?
- When does Vincerx Pharma report earnings?
- Should I buy Vincerx Pharma stock now?